Funds and ETFs Astellas Pharma Inc.

4503

JP3942400007

Name	Weight	AuM	1st Jan change	Investor Rating
DEMOCRACY INTERNATIONAL FUND ETF - USD	0.12%	0 M€	+4.65%	-
AMUNDI MSCI WORLD ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.10%	276 M€	+11.40%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - EUR	0.10%	0 M€	-.--%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - CHF	0.10%	0 M€	+8.31%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - B - USD	0.10%	0 M€	+11.06%
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	0.09%	0 M€	+6.98%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.07%	284 M€	-.--%
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - USD	0.07%	23 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - EUR	0.07%	786 M€	-.--%
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.06%	206 M€	-.--%
LYXOR NET ZERO 2050 S&P WORLD CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.06%	205 M€	-.--%
LEVERAGE SHARES 3X LONG TOTAL WORLD ETP SECURITIES - USD	0.06%	0 M€	0.00%	-
AMUNDI INDEX MSCI WORLD UCITS ETF - EUR	0.05%	1,166 M€	+0.26%	-
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.05%	607 M€	+0.05%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.05%	0 M€	+8.19%	-
IMGP RBA RESPONSIBLE GLOBAL ALLOCATION ETF - USD	0.04%	7 M€	+0.11%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.04%	0 M€	+7.83%	-
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	0.03%	0 M€	+3.48%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.03%	0 M€	+5.29%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.03%	0 M€	+5.52%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0.03%	0 M€	+3.25%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.02%	0 M€	+2.51%	-

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q1 2024 Earnings Release (Projected)

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,541 JPY

Average target price

2,009 JPY

Spread / Average Target

+30.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTELLAS PHARMA INC.	-8.19%	17.8B
ELI LILLY AND COMPANY	+32.36%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	358B
MERCK & CO., INC.	+19.46%	328B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	165B

Other Pharmaceuticals

Delayed Japan Exchange Other stock markets 08:41:33 2024-05-09 pm EDT			5-day change	1st Jan Change
1,548 ^JPY	+0.49%		-0.64%	-8.19%

May. 08	Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	CI
May. 02	Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	MT